What Is High-Risk HPV 58 and What Does It Mean?

HPV 58 is one of roughly fourteen human papillomavirus types classified as “high-risk” because of a proven ability to cause cervical cancer and other anogenital cancers. It belongs to the alpha-9 species group alongside HPV 16, the most studied and feared of all HPV types, which hints at both its biological behavior and its cancer-causing potential. Globally, HPV 58 accounts for a modest share of cervical cancers, but in East Asian populations it punches well above that average, ranking as the third most commonly detected HPV type in cervical cancer cases in that region.

Where HPV 58 Fits in the HPV Family

There are over 200 known types of HPV, but only a handful cause cancer. HPV 58 sits in the alpha-9 species group, a cluster that also includes HPV 16, 31, 33, 35, 52, and 67.¹ The types within a species group share genetic similarities and tend to behave in broadly comparable ways when it comes to infecting cells and evading the immune system. HPV 16 is the dominant cancer-causing type worldwide, responsible for about half of all cervical cancers. HPV 58 is a less prominent member of this group globally, but its role varies dramatically by geography.

Why Geography Matters So Much

If you live in North America or Europe, HPV 58 is an uncommon finding in cervical cancer specimens. Globally, it contributes to about 3.3% of cervical cancers. But that average obscures striking regional differences. In East Asia, HPV 58 has been found in much higher proportions of cervical cancer cases: around 28% in one Shanghai study, 16% in Korea, roughly 10% in both Hong Kong and Taiwan, and 8% in Japan.² HPV 58 consistently ranks as the third most commonly detected type in cervical cancer among Eastern Asian populations, behind HPV 16 and HPV 18.³

The reasons for this geographic clustering are not fully pinned down. Part of the explanation involves viral evolution and the co-migration of specific HPV lineages with human populations over tens of thousands of years. Part likely involves host genetics, including variations in immune-system genes that affect how well different populations clear certain HPV types. Whatever the cause, the practical upshot is that HPV 58 is a much bigger concern in some parts of the world than others.

How HPV 58 Causes Trouble in Cells

Like all high-risk HPV types, HPV 58 does its damage through proteins called E6 and E7. These viral proteins interfere with the cell’s built-in brakes on growth. The E7 protein from HPV 58 degrades a key tumor suppressor protein called pRb, which normally prevents cells from dividing uncontrollably. In lab studies, HPV 58 E7 reduced steady-state levels of pRb and another related protein (p130), effectively disabling cell-cycle checkpoints that would otherwise stop damaged cells from multiplying.⁴ Interestingly, the same research found that HPV 58 E7 degraded pRb less aggressively than HPV 16 E7. This may partly explain why HPV 58 is generally less potent than HPV 16 at driving cancer, though it is still clearly dangerous enough to warrant its high-risk classification.

Not All HPV 58 Variants Are Equal

One of the more important findings about HPV 58 is that its cancer risk is not uniform across all circulating strains. Specific genetic variants carry measurably higher risk. Variants with two particular amino acid changes in the E7 protein, known as T20I and G63S, were associated with a roughly four-and-a-half-fold higher risk of advanced precancerous lesions and invasive cervical cancer compared to other HPV 58 variants.⁵ These high-risk variants are disproportionately common in East Asian populations.³

This finding helps explain the geographic puzzle: HPV 58 may be especially concerning in East Asia not just because it is more common there, but because the specific strains circulating in that region are more oncogenic. If your HPV test comes back positive for type 58, the variant you carry influences your actual risk, though variant-level testing is not part of routine clinical practice yet.

Persistence and the Road to Precancer

Most HPV infections, including HPV 58, clear on their own within a year or two. Your immune system recognizes and eliminates the virus in the majority of cases. The danger lies in persistent infections, the ones that stick around. A large Chinese cohort study found that HPV 58 was one of the most commonly persistent high-risk types, with about 41% of detected infections persisting across follow-up visits. For comparison, HPV 52 had a similar persistence rate, while the overall clearance rate for high-risk HPV in that population was about 57%.⁶

When HPV 58 does persist, it carries real risk. A Korean cohort study found that persistent HPV 58 infection increased the risk of progressing from borderline cervical abnormalities to high-grade precancerous lesions by roughly 3.5 to nearly 6 times, a risk level comparable to persistent HPV 16 infection.⁷ A large prospective study from Portland, Oregon, placed HPV 58 in the higher-risk tier among non-16 types, with a seven-year risk of developing advanced precancer above 5%.⁸

In a Korean study that directly compared outcomes, the rate of high-grade precancer or worse among women with HPV 58 was about 59%, not statistically distinguishable from the 71% seen with HPV 16 in that particular population.⁹ These numbers are higher than the general population averages because the study was drawn from women already referred for further evaluation, but they underscore that HPV 58 should not be dismissed as a minor player.

Does Having Multiple HPV Types Make It Worse?

A question that comes up frequently: if you test positive for HPV 58 alongside other types, does co-infection increase your risk? A recent clinical study found that for HPV 58, being infected with multiple high-risk types at the same time did not increase the risk of developing precancerous lesions compared to a single HPV 58 infection alone.¹⁰ The same held true for HPV 16, 18, 33, and several other types. Each type seems to act more or less independently. So while having multiple HPV types detected might feel alarming on a test result, it does not necessarily mean your risk is compounded.

What the 9-Valent Vaccine Does for HPV 58

The good news is that HPV 58 is one of the types directly targeted by the 9-valent HPV vaccine (marketed as Gardasil 9), which covers types 6, 11, 16, 18, 31, 33, 45, 52, and 58.¹¹ In clinical trials, essentially all vaccinated participants developed antibodies against HPV 58.¹² If you or your child received Gardasil 9, HPV 58 is directly covered.

The older vaccines, however, tell a more complicated story. The bivalent vaccine (Cervarix) and the original quadrivalent vaccine (Gardasil) were designed to protect against HPV 16 and 18, plus types 6 and 11 for the quadrivalent version. Because HPV 58 is genetically related to HPV 16, researchers hoped for cross-protection, where antibodies generated against one type partially neutralize a related type. Follow-up data showed that bivalent vaccine recipients did develop detectable cross-neutralizing antibodies against HPV 58, and these antibodies were more prevalent in bivalent than quadrivalent recipients.¹³ But a systematic review and network meta-analysis found that the cross-protection these older vaccines offered against HPV 58 was not statistically significant. Only HPV 31 showed significant cross-protection from the bivalent and quadrivalent vaccines.¹⁴

In practical terms, if you received an older vaccine formulation, you should not assume you are protected against HPV 58. Continued cervical screening remains important regardless of vaccination status, but especially so if you were vaccinated before the 9-valent vaccine became available.

How Screening and Clinical Management Handle HPV 58

Modern HPV tests can identify specific types, and the clinical management guidelines increasingly use that information. The BD Onclarity assay, for example, groups HPV types into risk tiers. In a large prospective study, HPV 58 was grouped alongside types 31, 33, and 52 as the next-highest risk tier after HPV 16 and HPV 18/45. Women in this group had a three-year risk of advanced precancer high enough to justify colposcopy when combined with any abnormal cytology, but low enough for intensified follow-up when cytology was normal.¹⁵

If you receive a positive HPV 58 result, your doctor will typically combine that information with your Pap test results and medical history to decide on next steps. A positive HPV 58 result with normal cytology usually calls for closer follow-up rather than immediate biopsy. If cytology is abnormal, colposcopy is generally recommended. The key point: HPV 58 is taken seriously in clinical risk stratification, sitting in the second-highest risk category behind HPV 16.

HPV 58 Beyond the Cervix

While cervical cancer gets the most attention, HPV 58 can also contribute to other cancers. A comprehensive global analysis found that the nine HPV types covered by the 9-valent vaccine, which includes HPV 58, accounted for about 90% of all HPV-attributable anogenital cancers, including cancers of the vulva, vagina, anus, and penis.¹⁶ HPV 16 and 18 alone covered about 73% of that burden, meaning the additional five types in the 9-valent vaccine, including 58, collectively account for a meaningful slice of the remaining cases. HPV 58’s individual contribution to non-cervical cancers is small, but it is not zero, and the 9-valent vaccine’s expanded coverage addresses it.

HPV 58 in Men

HPV 58 is not limited to women. Men carry and transmit high-risk HPV types, though they are less likely to develop cancer from them (with the exception of anal and oropharyngeal cancers). A study in Wenzhou, China, tracked HPV in heterosexual couples and found that the median time to clearance for high-risk HPV in men was about 300 days.¹⁷ Having a partner with an active HPV infection and older age both increased the time it took for men to clear the virus. This underscores the importance of vaccination for boys and young men, not just to protect them from HPV-related cancers, but to reduce transmission to partners.

Methylation as a Future Screening Tool

One area of active research involves using the methylation status of the HPV 58 genome as a way to gauge how dangerous a particular infection is. Methylation is a chemical modification to DNA that can indicate how long a virus has been integrated into the host genome and how aggressively it is behaving. A study examining women infected with HPV 58 found that methylation of the virus’s L1 gene correlated with the severity of cervical disease: average methylation was about 12% in women with mild or no disease, 38% in those with moderate precancer, and 61% in those with advanced precancer.¹⁸

If validated in larger studies, methylation-based tests could help doctors distinguish between HPV 58 infections that are likely to clear on their own and those that are actively progressing toward cancer. That kind of triage would spare many women unnecessary procedures while catching dangerous infections earlier. The research is promising but not yet part of routine clinical practice.

The Ancient Roots of HPV 58

HPV types did not appear recently. They have been co-evolving with humans for hundreds of thousands of years. A phylogenetic analysis of HPV 58 genomes estimated that the deepest split between the major lineages of HPV 58 occurred roughly 400,000 to 480,000 years ago.¹⁹ More recently, Japan-specific clusters of HPV 58 variants diverged from other strains about 25,000 years ago, a timeframe that aligns with the migration and isolation of ancestral populations in the Japanese archipelago.

This deep evolutionary history explains why HPV type distributions vary so much by region. Specific viral lineages traveled with specific human populations as they migrated, split, and settled. The high-risk variants of HPV 58 prevalent in East Asia today are not random; they reflect a long shared history between virus and host. Understanding that history may eventually help researchers predict which variants are most dangerous and design next-generation vaccines tailored to the strains circulating in specific populations.